Efficacy and safety of Anti-pigmentation Activity of Pureplay BL Gel Serum

A Clinical Study to evaluate the efficacy and safety of Anti-pigmentation Activity of Pureplay BL Gel Serum - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/04/108972

Enrollment

Registered

2026-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: BL Gel Serum: Test Product: BL Gel Serum Dose: 5-6 drops applied on face and neck area twice a day (morning + night) Route of Administration: Topical Control Intervention1

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Male and female aged between 18 to 50. 2. Subject with fair to dark skin having at least one dark spot (Blemish). 3. Subject willing to give written informed consent 4. Women of child bearing potential must have a negative urine pregnancy test. 5. Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 6. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2. Volunteers with skin conditions such as eczema, psoriasis, etc 3. Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 4. Have open sore or open lesions in the treatment area 5. Have any condition that, in the opinion of the investigator,vwould confound the safety and efficacy assessments of the product. 6. Have participated in any interventional clinical trial in the previous 30 days. 7. Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 8. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 9. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

Measure	Time frame
1. Skin Gloss (Glossymeter) 2. Skin Hydration (Corneometer) 3. TEWL (Tewameter) 4. Skin Firmness(R0) (Cutometer) 5. Skin Elasticity(R2) (Cutometer) 6. Skin Melanin (Mexameter) 7. Skin Lightness (Colorimeter) 8. Dermat Evalution Timepoint: At Day 0, 7, 14, 18	—

Secondary

Measure	Time frame
1. HD Imaging with DSLRTimepoint: At Day 0, 18	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results